Oncolytic herpes simplex virus (oHSV) can be genetically engineered to target cancer cells while sparing normal cells. This leads to the direct killing of cancer cells and the activation of the host immunity to recognize and attack the tumor. Different variants of oHSV have been developed to optimize its antitumor effects.

2018年12月18日 · We reviewed the immunotherapy mechanism of the oHSV and provided a series of cases. We also pointed out that an in-depth study of the application of oHSV in cancer treatment will potentially benefits cancer patients more.

2021年9月3日 · We found: (1) Treatment with MEKi Trametinib augmented oHSV oncolytic activity in BRAF V600E-mutated tumor cells. (2) Combination treatment with oHSV and MEKi Trametinib enhanced virus replication mediated by down-regulation of STAT1 and PKR expression or phosphorylation in BRAF V600E-mutated tumor cells as well as BRAF wt/KRAS-mutated tumor cells.

2023年10月12日 · oHSV通过选择性地在肿瘤细胞中复制并逃避抗病毒免疫来直接破坏肿瘤细胞，并刺激抗肿瘤免疫反应，这是oHSV杀死癌细胞的主要机制。 多种策略可以提高oHSV在肿瘤治疗中的疗效，包括设计新型 oHSV、增加oHSV向肿瘤细胞的全身递送和联合治疗。

Oncolytic viruses, such as oncolytic herpes simplex virus (oHSV), are a new class of cancer therapeutic, which selectively replicate and kill cancer cells, while inducing an inflammatory microenvironment, immunovirotherapy. Recently, an oHSV (talimogene laherparepvec) has been approved for the treatment of advanced melanoma.

In this category of oncolytic viral drugs human pathogens herpes simplex virus (HSV) is especially suitable for the cause. Although most viral infection causes antiviral reaction in the host, HSV has multiple mechanisms to evade those responses.

2020年12月28日 · The efficacy of oHSV-CD/5-FC treatment against UM cells was demonstrated in vitro and in vivo. We reported that oHSV-1 has the ability to down-regulate IL-6 and inhibit the epithelial–mesenchymal transition (EMT) phenotype. The rate-limiting enzyme, dihydropyrimidine dehydrogenase (DPD, DPYD), was also down-regulated.

2019年7月9日 · Among viral therapeutics, genetically engineered oncolytic herpes simplex viruses (oHSV) offer several advantages. HSV-1 has been extensively studied and its essential and non-essential genes...

2021年5月13日 · Oncolytic viruses (OVs), such as the oncolytic herpes simplex virus (oHSV), are a rapidly growing treatment strategy in the field of cancer immunotherapy. OVs, including oHSV, selectively replicate in and kill cancer cells (sparing healthy/normal cells) …

tem, and tailoring the immune response to-ward tumor clearance is a far better strategy than directly lysing the tumor outright with virus. The next field-shaping question for OVs is how to convert a patient’s immune response against their tumor. The talks this year focused on whether OVs can cause the emergence of a strong anti-tumor immunity